GLP-1 basics before comparing providers

GLP-1 stands for glucagon-like peptide-1, a hormone released by the intestine. GLP-1 receptor agonists reproduce some of that hormone’s effects. They influence appetite and calorie intake, slow stomach emptying to varying degrees, stimulate insulin release when glucose is elevated and reduce glucagon, a hormone that can raise blood sugar. Those overlapping actions explain why the class is used in both diabetes and chronic weight management. Wegovy’s FDA label and Foundayo’s FDA label describe these mechanisms.

The drugs do not simply “shut off hunger,” and reduced appetite is not their only effect. Slower gastric emptying can contribute to fullness and gastrointestinal symptoms, while glucose-dependent insulin and glucagon effects can improve blood-sugar measures. The strength and persistence of each effect differ by medication and person. Tirzepatide also activates the GIP receptor, so it is more accurately described as a dual GIP/GLP-1 medicine rather than a GLP-1-only drug. Zepbound’s FDA label identifies both targets.

Four active ingredients in this family have FDA-approved weight-management brands. Saxenda contains liraglutide and is a daily injection. Wegovy contains semaglutide and comes in weekly injection and daily tablet forms; the injection family includes the higher-strength Wegovy HD approved in March 2026. Zepbound contains tirzepatide and is a weekly injection. Foundayo contains orforglipron and is a daily tablet. The respective FDA labels define the products and approved uses: Saxenda, Wegovy, Zepbound and Foundayo.

The FDA approved Foundayo on April 1, 2026, for long-term weight reduction and maintenance in qualifying adults when paired with reduced-calorie eating and increased physical activity. FDA describes it as an oral GLP-1 receptor partial agonist. It was a major addition, but it was not the only oral weight-management GLP-1 available by mid-2026: Wegovy tablets were also FDA approved. The FDA’s Foundayo announcement verifies the approval date and indication, while the current Wegovy label confirms its oral and injectable forms.

Brand names matter. A diabetes brand containing a familiar ingredient is not automatically FDA approved for weight management, and a compounded product is not the FDA-approved brand. Confirm the exact name, active ingredient, form and approved indication before comparing offers.

FDA labels report averages from controlled trials, not guaranteed outcomes. In a 56-week Saxenda trial involving adults without diabetes, average weight change was about 7.4% with Saxenda versus 3.0% with placebo. In a 68-week Wegovy injection trial involving adults without diabetes, the averages were 14.9% versus 2.4%. A later 72-week Wegovy HD trial reported 18.8% versus 3.9%. The Saxenda label and Wegovy label provide the trial tables.

For Zepbound, a 72-week trial in adults without diabetes reported average losses ranging from 15.0% to 20.9% across studied strengths, compared with 3.1% for placebo. In participants with type 2 diabetes, the corresponding averages were 12.8% to 14.7% versus 3.2%. Foundayo’s 72-week trials reported averages of 7.4% to 11.1% versus 2.1% in participants without diabetes and 5.1% to 9.6% versus 2.5% in participants with type 2 diabetes. The Zepbound and Foundayo labels contain these results.

These numbers should not be treated as a head-to-head ranking. The trials used different populations, products, study periods and analytical methods. A credible provider should explain the evidence for the specific medication being offered, including the placebo result and the population studied.

For adults, the usual FDA-aligned threshold for chronic weight-management medication is a BMI of 30 or higher, or a BMI of 27 or higher with a weight-related condition such as high blood pressure or type 2 diabetes. BMI is a screening threshold, not a complete treatment decision. Medical history, current medicines, pregnancy plans, side effects, expected benefit and cost also belong in the evaluation. NIDDK’s weight-management medication guide explains the criteria and decision factors.

Nausea, diarrhea, vomiting, constipation, abdominal discomfort, indigestion and reflux are among the recurring side effects across these labels. The serious issues to raise with a clinician include pancreatitis, gallbladder disease, kidney injury related to dehydration, severe gastrointestinal reactions, serious allergic reactions and low blood sugar—especially when treatment is combined with insulin or medicines that increase insulin release. Some labels also call for attention to diabetic retinopathy and the risk of aspiration during anesthesia or deep sedation. These warnings are detailed in the FDA labels for Saxenda, Wegovy, Zepbound and Foundayo.

All four carry a boxed warning concerning thyroid C-cell tumors and should not be used by people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. The labels state that the relevance of the animal findings to humans has not been determined. Pregnancy, planned procedures and every prescription, nonprescription drug and supplement should be disclosed during clinical review.

Insurance coverage is plan-specific; NIDDK states that some plans cover weight-management medications and others do not. Before enrolling, ask the insurer about the exact brand, prior authorization, renewal criteria, quantity limits and the pharmacy network. For cash-pay care, compare the full recurring amount rather than one promotional number: medication, visits, laboratory work, shipping, refill support and cancellation terms can be separate line items. NIDDK recommends including cost in the medication decision.

Manufacturer-direct channels may combine pharmacy fulfillment, self-pay or insurance paths and support services. As of July 2026, LillyDirect describes delivery or pickup for selected prescribed Lilly medicines, insurance or self-pay options for selected products, and prior-authorization coordination where applicable. That is a dated program snapshot, not a promise that a particular medicine, price or service will remain available; terms can change.

Telehealth is a way to receive clinical and pharmacy services, not proof that the product is FDA approved. A safer offer identifies the licensed prescriber, exact medication, dispensing pharmacy and follow-up plan. Use this checklist before payment:

Compounded semaglutide or tirzepatide is not the same product as FDA-approved Wegovy or Zepbound. Compounded drugs do not undergo FDA premarket review for safety, effectiveness or quality, and FDA has warned against claims that a compounded GLP-1 is a generic or clinically proven equivalent of an approved brand. Compounding can have a role when a patient’s needs cannot be met by an available approved drug, but that requires a more careful source and clinician conversation. See the compounded GLP-1 red-flags guide and the FDA’s unapproved GLP-1 warning.

Weight change is rarely a straight line. NIDDK reports that most medication-associated weight loss occurs during the first six months, so a slower phase or plateau is not automatically evidence of failure. Results vary, and the labels studied these medicines alongside reduced-calorie eating and increased physical activity—not as stand-alone replacements for those behaviors. NIDDK also states that people will probably regain some weight after stopping, although the amount varies.

Before starting, ask how progress will be assessed, what follow-up is included and what the plan would be if benefits level off, side effects become difficult, coverage ends or treatment stops. Make medication and health decisions with a licensed clinician who knows your history.

GLP-1 (glucagon-like peptide-1) receptor agonists mimic a gut hormone that increases insulin secretion in response to meals, slows gastric emptying, and can reduce appetite. Clinically, GLP-1 receptor agonists are prescribed for type 2 diabetes and-at specific doses and approved indications-for chronic weight management. Different molecules and formulations exist; some are approved by the U.S. Food and Drug Administration (FDA) for diabetes, some for weight management, and others may be compounded or sold without FDA approval. It's important to distinguish FDA-approved brand medications from compounded or unapproved products.

FDA-approved GLP-1 drugs come with prescribing information that lists indications, dosing schedules, contraindications, boxed warnings (if any), and adverse reactions. For example, Wegovy (semaglutide) and Zepbound (tirzepatide) each have prescribing information documents that clinicians use to guide safe prescribing. Compounded products are made by pharmacies to create formulations not commercially available; they are not FDA-approved, may lack standardized dosing, and have been the subject of safety alerts. The FDA has warned that some unapproved GLP-1 products are being marketed or sold for weight loss with incorrect or unclear labeling and dosing, and that such products can cause dosing errors and adverse events.

Large randomized trials demonstrate that some GLP-1 and related drugs produce substantial average weight loss compared with placebo in adults with overweight or obesity when used with lifestyle interventions. For semaglutide, the STEP 1 trial found that semaglutide 2.4 mg produced materially greater average weight loss than placebo at 68 weeks in adults with overweight or obesity. For tirzepatide, the SURMOUNT-1 trial found that tirzepatide produced large average weight reductions versus placebo at 72 weeks. These trials enrolled specific populations under controlled conditions; actual results in community practice can vary. There are also cardiovascular outcomes trials-such as SELECT for semaglutide-that provide context on cardiovascular effects in selected populations with established cardiovascular disease and overweight or obesity.

GLP-1 medications commonly cause gastrointestinal side effects including nausea, vomiting, diarrhea, and constipation, particularly during dose escalation. Prescribing information documents list contraindications and adverse reactions; some GLP-1 drugs also carry boxed warnings that clinicians must consider when prescribing. For specific medicines, consult their official prescribing information to review boxed warnings, contraindications, and full adverse reaction profiles before use. The FDA has additionally emphasized safety risks from unapproved products, including dosing errors and adverse events.

Cost has two main parts: the medication price (what the drug itself costs, which varies by brand, dose, and insurer coverage) and any membership or platform fees charged by telehealth services or clinics. Brand, FDA-approved GLP-1 medications have manufacturer prices and may be covered by some insurers under medical or pharmacy benefits depending on the indication; compounded or unapproved products may be priced differently but carry higher regulatory and safety risk. Separating medication cost from platform or membership fees is important when comparing options. This guide does not provide specific price figures; consult pharmacies, insurers, and service providers for current pricing and coverage information.

When comparing clinicians, telehealth platforms, or pharmacies, ask direct questions to assess safety, expertise, and ongoing care plans. Key questions include whether the provider will: review your full medical history and current medications, order or review required baseline and follow-up tests, discuss FDA-approved versus compounded/unapproved products and their risks, explain dosing escalation plans and common side effects, provide blood glucose monitoring instructions if you have diabetes or use other glucose-lowering drugs, and outline costs (medication vs platform fees) and follow-up frequency. Also ask who will manage adverse effects and how to get urgent help if needed.

The FDA has warned about unapproved GLP-1 products that are being marketed and sold to consumers, sometimes labeled for 'research use only' or 'not for human use' while being offered for weight loss. These products can lead to dosing errors and adverse events. Other red flags include providers who do not review your full medical history, who skip baseline testing, who push compounded or unapproved products without discussing risks, or who refuse to provide an emergency plan for adverse events. Prefer clinicians and pharmacies that reference FDA-approved prescribing information and provide clear documentation.

GLP-1 medications are typically prescribed together with lifestyle counseling (dietary guidance, physical activity, and behavioral support) for weight management. Expect dose titration schedules for many agents to reduce side effects; clinicians should explain the escalation plan and what to expect. If stopping therapy, clinicians should discuss how to transition and manage potential weight regain or recurrent appetite changes. Treatment plans are individualized and should be set collaboratively with a qualified clinician.

Prepare to provide a complete medical history, current medication list (including over-the-counter and herbal products), insurance information, and any previous records related to weight loss or diabetes care. Ask the clinician to document which specific medication brand and formulation they plan to prescribe, to provide the prescribing information, and to explain necessary laboratory tests and follow-up schedule.